Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Is there a difference between low-molecular-weight heparins?].

Jan Eritsland1

  • 1Hjertemedisinsk avdeling, Ullevål universitetssykehus, 0407 Oslo. jan.eritsland@ulleval.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel cardiac extracellular matrix biomarkers in STEMI: Associations with ischemic injury and long-term mortality.

PloS one·2024
Same author

Blood Milieu in Acute Myocardial Infarction Reprograms Human Macrophages for Trauma Repair.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2022
Same author

High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI.

Open heart·2021
Same author

Neutrophil extracellular trap components and myocardial recovery in post-ischemic acute heart failure.

PloS one·2020
Same author

Remote Ischemic Conditioning in Patients with Acute Coronary Syndromes: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.

Clinical epidemiology·2020
Same author

Double-Stranded DNA and NETs Components in Relation to Clinical Outcome After ST-Elevation Myocardial Infarction.

Scientific reports·2020

Low-molecular-weight heparins (LMWHs) differ structurally and pharmacologically, impacting their anticoagulant properties. Clinical use requires adherence to approved indications and doses, avoiding patient switching between different LMWH products.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Clinical Medicine

Background:

  • Low-molecular-weight heparins (LMWHs) are often grouped but exhibit structural and pharmacological dissimilarities.
  • Variations in molecular size spectrum and in vitro anticoagulant properties, particularly the anti-factor Xa : anti-factor IIa activity ratio, exist among LMWH products.
  • The clinical implications of these inter-product differences remain largely unelucidated.

Purpose of the Study:

  • To highlight the structural and pharmacological heterogeneity of low-molecular-weight heparins.
  • To emphasize the importance of using LMWHs according to approved indications and established effective/safe dosages.
  • To discuss the implications of switching between different LMWH products and introduce Fondaparinux.

Main Methods:

Related Experiment Videos

  • Comparative analysis of structural and pharmacological properties of different low-molecular-weight heparin products.
  • Review of existing clinical studies comparing the efficacy and safety of LMWHs.
  • Examination of the pharmacological profile of Fondaparinux, a synthetic pentasaccharide.

Main Results:

  • Significant structural and pharmacological differences exist among low-molecular-weight heparins, affecting their anti-factor Xa and anti-factor IIa activities.
  • Limited clinical studies have not demonstrated significant outcome differences between two specific LMWHs.
  • Fondaparinux exhibits a distinct anti-factor Xa : anti-factor IIa ratio (1:0) and a promising efficacy/safety profile for specific indications.

Conclusions:

  • Low-molecular-weight heparins should be prescribed based on their specific approved indications and demonstrated clinical efficacy and safety.
  • Switching between different low-molecular-weight heparin products within the same patient is not recommended.
  • Fondaparinux represents a distinct entity with a defined role in prophylaxis, currently limited to orthopaedic surgery.